Podcasts, panels, and archives of the first NCI-designated cancer centers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Can you name the first NCI-designated cancer centers?

The answer to  this question is anything but straightforward—in part because the contenders predate NCI’s definition of a “cancer center” (The Cancer Letter, July 9, 2021).   

Four institutions, all contributors to the Cancer History Project, hold the “first” of the following designations: 


Contributor spotlight: Fox Chase Cancer Center

Just 40 years ago, the Fox Chase Cancer Center of today—a place known for providing top-level patient care and conducting cutting-edge research—was merely an idea. As Fox Chase transitions into its role as a member of Temple University Health System, it’s worth remembering that the center was formed by a similar integration not so long ago.

The concept of the comprehensive cancer center—a facility where treatment and research are united under one roof—came into being when President Richard Nixon signed the National Cancer Act in 1971. Widely known as the launch of the “War on Cancer,” the act included funding for a series of such centers.

At the time, prominent cancer research institutions the country over, including Philadelphia’s own Institute for Cancer Research, began to scout for suitable clinical partners. Once merged with a hospital, they would be eligible to receive federal funds.

For the Institute for Cancer Research, the natural choice for a collaborator was the American Oncologic Hospital—one of the oldest cancer hospitals in the country, having been founded in 1904. After decades of struggling to find larger quarters, the organization had moved to the Fox Chase section of northeast Philadelphia—right next to the institute—in 1968.


Then vs. Now: Panel Discussions

Last December, leaders in oncology gathered to commemorate the 1971 signing of the National Cancer Act at the Nixon National Conference.

A full recording of the conference appears here.

The second annual conference will be held Dec. 7-8 at the Richard Nixon Presidential Library and Museum.

Clinicians, researchers, journalists, NCI-designated cancer center directors, patients, patient advocates, ethicists, medical professionals and public health officials will convene at the 2022 Nixon National Cancer Conference, a two-day gathering focusing on areas where cancer is leading the solution to patient problems.

The 2022 Nixon National Cancer Conference will open with a reception and dinner sponsored by City of Hope Orange County on Dec. 7 at 5:30 p.m. PST followed by panel discussions and a luncheon sponsored by the Hoag Family Cancer Institute on Dec. 8, at 9:00 a.m. PST.

On July 29, 2021, the Cancer History Project convened panelists Candace S. Johnson, president and CEO of Roswell Park Comprehensive Cancer Center, Craig B. Thompson, president and CEO of Memorial Sloan Kettering Cancer Center, and Peter WT Pisters, president of MD Anderson Cancer Center, for a two hour Zoom session moderated by co-editor Otis W. Brawley.  

The panelists discussed oncology’s history, beginning with the National Cancer Act, and mapped out a more equitable future for oncology. 

Now, the Cancer History Project has reformatted the panel into a podcast

A collection of panels convened by the Cancer History Project appears here


This column features the latest posts to the Cancer History Project by our growing list of contributors

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available.  

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj, or follow our podcast.

Is your institution a contributor to the Cancer History Project? Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. 

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login